Betamethasone

證據等級: L5

預測適應症: 10 個

Betamethasone: From Inflammatory/Autoimmune Conditions to Alopecia Areata

One-Sentence Summary

Betamethasone is a potent synthetic glucocorticoid widely used for its anti-inflammatory and immunosuppressive properties across a broad range of inflammatory and autoimmune conditions. The TxGNN model predicts it may be effective for Alopecia Areata, with 7 clinical trials and 20 publications currently supporting this direction — the strongest evidence among all 10 predicted indications in this report.

Quick Overview

Item	Content
Original Indication	No Philippines FDA registration data available (betamethasone is a well-established glucocorticoid for inflammatory/autoimmune conditions)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.97%
Evidence Level	L1
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Betamethasone is a synthetic glucocorticoid that acts primarily through activation of the glucocorticoid receptor (GR-α). Its core mechanisms include: (1) downregulation of Th1 pro-inflammatory cytokines such as IL-2, IFN-γ, and TNF-α; (2) induction of T-cell apoptosis; (3) upregulation of TGF-β to restore immune privilege microenvironments; and (4) suppression of NF-κB activation. Currently, detailed mechanism of action data from DrugBank is not available in this dataset, but betamethasone’s pharmacodynamic profile is well-characterized in the wider literature.

Alopecia areata (AA) is an autoimmune disorder in which CD8+ NKG2D+ T cells breach the hair follicle’s immune privilege zone and launch a targeted attack on the follicle. This pathology maps directly onto betamethasone’s mechanisms: suppressing T-cell-mediated cytokine cascades, inducing apoptosis of the attacking lymphocytes, and re-establishing the TGF-β-dependent immune privilege environment that protects hair follicles under normal conditions.

What makes this prediction especially robust is the convergence of mechanism with multi-route clinical validation. Topical formulations (dipropionate), intralesional injection (acetonide), and oral mini-pulse regimens have each been studied in controlled trials for AA, and all three routes have demonstrated clinical benefit. This breadth of validated delivery options considerably strengthens the translational case.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06786689	Phase 2	Completed	60	Head-to-head RCT comparing betamethasone oral mini-pulse (BOMP) vs. weekly azathioprine pulse in moderate-to-severe AA; primary betamethasone intervention with full efficacy and safety data
NCT05803070	N/A	Unknown	59	Topical cetirizine 1% vs. topical betamethasone valerate 0.1% in localized AA; direct head-to-head comparison with betamethasone as the reference standard
NCT06087796	Phase 1	Unknown	60	Topical pentoxifylline 2% gel and topical metformin 10% gel vs. topical betamethasone valerate 0.1% cream in patchy AA; betamethasone as active comparator, control-arm data extractable
NCT02350023	Phase 4	Completed	50	First head-to-head comparison of topical betamethasone vs. topical latanoprost in localized AA; completed trial with efficacy endpoint data
NCT03535233	Phase 4	Completed	40	Combined topical minoxidil 5% + potent topical corticosteroid (including betamethasone-class agents) vs. intralesional triamcinolone in AA; comparative design
NCT04207931	Phase 4	Recruiting	250	Multicenter study of Central Centrifugal Cicatricial Alopecia (CCCA) treatment outcomes; different alopecia subtype — indirect class-level reference only
NCT01111981	Phase 4	Unknown	30	Clobetasol propionate 0.05% foam in CCCA; different drug and different alopecia subtype — indirect corticosteroid class reference only

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37870096	2023	Network Meta-analysis	Cochrane Database of Systematic Reviews	Comprehensive NMA of all AA treatments including topical and systemic corticosteroids; highest-level evidence synthesis for the field
39393548	2025	RCT	J Am Acad Dermatol	Microneedle transdermal delivery of compound betamethasone in AA; demonstrated comparable efficacy to intralesional injection with significantly reduced patient pain
40519428	2025	Prospective Clinical Study	Cureus	Oral betamethasone mini-pulse regimen in moderate-to-severe AA; evaluates efficacy, safety, and feasibility of intermittent systemic dosing
38623137	2024	RCT	Cureus	Topical betamethasone dipropionate vs. topical minoxidil in AA; direct comparative efficacy trial
34400956	2021	RCT	Iran J Pharm Res	Randomized double-blind placebo-controlled trial: oral betamethasone pulse (3 mg/week) vs. methotrexate vs. combination in severe AA (n=36)
37992355	2023	Review	Dermatol Pract Concept	Systematic review of corticosteroid pulse therapy in AA: efficacy rates, relapse patterns, adverse effects profile, and prognostic factors
32594786	2022	RCT	J Dermatol Treat	Within-patient randomized controlled trial directly comparing intralesional betamethasone vs. intralesional triamcinolone acetonide in localized AA
36257912	2022	Comparative RCT	Dermatol Ther	Six-arm blinded RCT evaluating latanoprost vs. minoxidil vs. betamethasone and combinations in AA (n=108 total, 18 per arm)
36114868	2023	Comparative RCT	Arch Dermatol Res	Fractional CO₂ laser alone vs. in combination with betamethasone valerate in AA; clinical and dermoscopic outcome evaluation
26691357	2015	Comparative Study	J Coll Physicians Surg Pak	Intralesional triamcinolone acetonide vs. topical betamethasone valerate in localized AA; early controlled comparison supporting topical betamethasone as a standard-of-care reference

Philippines Market Information

Betamethasone has no registered products in the Philippines FDA database based on available data (0 licenses, status: Not Marketed).

Important Note: This likely reflects a data gap rather than true unavailability. Betamethasone is one of the most widely distributed generic corticosteroids globally and is included on the WHO Essential Medicines List. Direct verification with the Philippines FDA (Food and Drug Administration) registry is strongly recommended before drawing regulatory conclusions.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Betamethasone in alopecia areata is supported by a Cochrane Network Meta-analysis, multiple completed RCTs, and a mechanistically coherent immunosuppressive rationale (GR-α activation → T-cell suppression → restoration of follicular immune privilege). The evidence base meets L1 criteria and spans three clinically validated routes of administration, making this a strong repurposing candidate.

To proceed, the following is needed:

Verify Philippines FDA registration status directly with the FDA Philippines registry, as current data showing 0 registrations likely reflects a data coverage gap rather than genuine absence from the market
Obtain the full betamethasone package insert to document warnings, contraindications, and drug-drug interactions — currently all safety fields are absent from this evidence pack
Retrieve DrugBank MOA data (DB00443) to formally document the glucocorticoid receptor mechanism for regulatory dossier purposes
Define the target indication scope: clarify whether to pursue topical (dipropionate for mild/localized AA), intralesional (acetonide for patchy AA), or oral mini-pulse (moderate-to-severe AA), as each route has distinct evidence, safety profiles, and regulatory implications
Establish a monitoring plan covering: HPA axis suppression (systemic routes), local skin atrophy (topical routes), infection risk, metabolic effects, and adrenal recovery during tapering
Confirm that any submission pathway accounts for the lack of formal Phase 3 data specifically in the Philippines patient population, and assess whether bridging studies are required by the Philippines FDA
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.